The two inhaled long-acting β 2-adrenoceptor agonists, salmeterol and formoterol, have
been studied extensively since their introduction in the early 1990s. In this review we …

Objective To review the pharmacology of the long-acting inhaled β 2-agonists, salmeterol
and formoterol, summarize results of their clinical trials, evaluate their safety records, and …

Salmeterol and formoterol are both long-acting β 2-adrenoceptor agonists (β 2-agonists).
They both provide excellent bronchodilating and bronchoprotective effects in patients with …

Despite concerns in the 1970s and 1980s about the safety of short‐acting β2‐agonists, it is
now generally accepted that these agents, used at appropriate doses, provide safe and …

Long-acting β 2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in
the treatments of chronic obstructive lung diseases. Although no specific indications …

Salmeterol and formoterol belong to a new class of inhaled β2‐agonists with a prolonged
duration of action. At the time these agents were introduced, there was uncertainty regarding …

The major clinical outcomes measured in evaluating the responses to pharmacotherapy in
patients with chronic obstructive pulmonary disease (COPD) include the severity of dyspnea …

Long-acting β 2 agonist bronchodilators (eg formoterol, salmeterol) are a new interesting
therapeutic option for patients with chronic obstructive pulmonary disease (COPD). In the …

OBJECTIVE: To describe the pathogenesis of chronic obstructive pulmonary disease
(COPD) and mechanisms of benefit, formulations available, drug costs, pharmacokinetic …

For patients whose asthma is not adequately controlled with inhaled corticosteroid (ICS)
therapy alone, increasing the dose of ICS or the addition of a long-acting β2-agonist is …